WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643 (Pirinixic Acid), cataloged as A4305 by APExBIO, is a selective PPARα agonist with an IC50 of 10.11 µM for human PPARα, enabling precise modulation of lipid metabolism and inflammatory pathways (APExBIO). Aliphatic α-substitution increases its balanced dual PPARα/γ agonist activity in the low micromolar range. Oral dosing in high-fat-fed rat models (3 mg/kg/day, 2 weeks) leads to significant reductions in plasma glucose, triglycerides, leptin, and hepatic triglyceride content while improving insulin sensitivity (Bao et al., 2025). WY-14643 robustly downregulates VCAM-1 expression in endothelial cells, reducing inflammatory cell adhesion. The compound is insoluble in water but highly soluble in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance), and requires storage at -20°C. These properties make WY-14643 a key reagent for metabolic disorder, NAFLD, and endothelial inflammation studies.

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors critical for regulating lipid metabolism, energy homeostasis, and inflammation (Bao et al., 2025). PPARα activation induces fatty acid oxidation, reduces triglyceride synthesis, and modulates inflammatory gene expression. Dysregulation of PPARα-mediated pathways is implicated in metabolic disorders such as type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. WY-14643 (Pirinixic Acid) is a synthetic ligand engineered for high selectivity and potency toward PPARα, providing a robust tool to dissect the biological consequences of PPARα and PPARγ modulation (APExBIO). By selectively activating PPARα, WY-14643 enables researchers to interrogate mechanisms underlying metabolic homeostasis, inflammation, and related pathologies with high specificity.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds directly to the ligand-binding domain of PPARα, acting as a full agonist and inducing receptor-mediated transcriptional activity (APExBIO). The reported IC50 for human PPARα is 10.11 µM, reflecting high potency. Upon activation, PPARα forms heterodimers with retinoid X receptors (RXRs) and binds to peroxisome proliferator response elements (PPREs) in target gene promoters. This leads to upregulation of genes involved in fatty acid β-oxidation and downregulation of genes mediating inflammation (e.g., vascular cell adhesion molecule-1, VCAM-1). Aliphatic α-substitution of WY-14643 further enhances its activity on both PPARα and PPARγ, resulting in balanced dual agonism in the low micromolar range. In endothelial cells, WY-14643 decreases VCAM-1 expression, reducing leukocyte adhesion and inflammatory infiltration. In metabolic tissues, it promotes fatty acid oxidation, decreases triglyceride accumulation, and improves insulin sensitivity.

Evidence & Benchmarks

• WY-14643 (Pirinixic Acid) selectively activates human PPARα with an IC50 of 10.11 µM, as established by in vitro binding assays (APExBIO).
• Aliphatic α-substitution enhances dual PPARα/γ agonist activity, achieving balanced modulation in the low micromolar range (internal benchmark).
• Oral administration of 3 mg/kg/day WY-14643 for 2 weeks in high-fat-fed rats significantly reduced plasma glucose, triglycerides, leptin, muscle triglycerides, and liver triglyceride content, and improved insulin sensitivity, with no increase in body weight (Bao et al., 2025).
• WY-14643 downregulates VCAM-1 in endothelial cells, reducing inflammatory cell adhesion and demonstrating anti-inflammatory effects (Bao et al., 2025).
• In tumor microenvironment models, PPARα activation by WY-14643 modulates tissue factor (TF) expression, influencing macrophage infiltration and NK cell activity (Bao et al., 2025).

This review builds upon and extends the comprehensive workflow guidance in WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research by integrating recent multiomics data and clarifying its role in the tumor microenvironment.

Applications, Limits & Misconceptions

WY-14643 is widely employed in metabolic disorder research, including type 2 diabetes, NAFLD, and metabolic syndrome. It is used in both in vitro and in vivo models to assess PPARα-mediated modulation of lipid metabolism, inflammation, and energy homeostasis. The compound's capacity to reduce VCAM-1 expression makes it particularly valuable in studies of endothelial inflammation. Additionally, WY-14643 is applied in tumor microenvironment research to elucidate PPARα’s role in tissue factor regulation and immune cell infiltration (Bao et al., 2025).

Common Pitfalls or Misconceptions

• WY-14643 is insoluble in water and should not be used in aqueous buffers; optimal dissolution is achieved in DMSO or ethanol with ultrasonic assistance (APExBIO).
• Long-term storage of WY-14643 solutions is not recommended; aliquots should be stored at -20°C and prepared fresh for experiments.
• WY-14643 is not a pan-PPAR agonist; its primary activity is toward PPARα, with secondary activity toward PPARγ only after specific aliphatic α-substitution.
• Observed effects in animal models may not directly translate to human clinical outcomes due to species-specific differences in PPAR expression and regulation.
• Improvement in insulin sensitivity and lipid parameters requires controlled dosing and dietary context; results may vary outside high-fat-fed models.

For scenario-driven protocol advice and troubleshooting, see Scenario-Driven Solutions for WY-14643 (Pirinixic Acid), which this article extends by providing detailed chemical handling guidance and updated mechanistic evidence.

Workflow Integration & Parameters

WY-14643 (Pirinixic Acid) is supplied as a solid by APExBIO and should be stored at -20°C. The compound is insoluble in water, but dissolves readily in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic assistance). For optimal solubility, warming to 37°C and ultrasonic shaking are recommended. Working solutions should be prepared fresh and not stored long-term. In animal studies, a standard protocol involves oral administration at 3 mg/kg/day for 2 weeks in high-fat-fed rat models. In vitro concentrations are typically in the 1–50 µM range, depending on cell type and experimental design. WY-14643 is compatible with PPAR signaling pathway assays, metabolic flux analysis, and inflammation models. For advanced troubleshooting and comparative protocols, consult WY-14643: A Selective PPARα Agonist for Metabolic Research, which this article updates with recent mechanistic insights and storage recommendations.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a benchmark PPARα agonist for metabolic and inflammation research. Its high selectivity, reproducible efficacy, and robust anti-inflammatory effects empower studies in lipid metabolism, insulin sensitivity, and endothelial inflammation. APExBIO’s A4305 reagent supports reliable workflows in both basic and translational research. Ongoing multiomics studies and tumor microenvironment models continue to reveal new roles for PPARα modulation in disease. Careful attention to compound handling, solubility, and species-specific responses will maximize research impact.